Experienced in Ectodermal Dysplasias

Tania F. Cestari

Porto Alegre, RS, BR 
Experienced in Ectodermal Dysplasias
Porto Alegre, RS, BR 
OverviewLocationsClinical Research

Overview

Tania Cestari practices in Porto Alegre, Brazil. Ms. Cestari is rated as an Experienced expert by MediFind in the treatment of Ectodermal Dysplasias. Her top areas of expertise are Focal Dermal Hypoplasia, Melasma, Psoriasis, and Milia.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Ectodermal Dysplasias.

Gender
Female

Locations

Porto Alegre, RS, Brazil
Other Locations
Rio Grande, RS, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, Topical Corticosteroid
Study Phase: Phase 3

38 Total Publications

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.
Journal: Anais brasileiros de dermatologia
Published: June 06, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cestari's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile